Navigation Links
To prevent leukemia's dreaded return, go for the stem cells
Date:4/5/2012

Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out chronic myeloid leukemia (CML) for good.

That's in contrast to the vast majority of CML patients taking drugs like imatinib (aka Gleevec) today, who often go into remission only to see their cancer return again. It is those lingering leukemia stem cells, which stubbornly resist existing therapies, that fuel the cancer's comeback.

"Imatinib inhibits the oncoprotein [that drives CML] and it is incredibly effective at putting patients into remission," said Scott Armstrong of Harvard Medical School. "But there is growing evidence that this doesn't rid the body of the most immature cancer cells. The question is: How can we eradicate those cells?"

The Cell Stem Cell study focused on a pathway known to be important in blood stem cells during development but not in adulthood. The new findings in mice suggest that leukemia stem cells revert back to their dependence on that early developmental pathway.

That leaves leukemia stem cells vulnerable to treatments aimed at the so-called β-catenin pathway in a way that normal blood stem cells aren't. The evidence shows that imatinib plus the loss of β-catenin can help to prevent recurrence of the disease. β-catenin inhibitors given to mice also helped to eliminate leukemia stem cells, as did a pain-relieving drug already in use that lowers β-catenin levels, if indirectly.

Armstrong says there is more work to do to ensure that β-catenin blockers would work in the same way in humans that they do in the mice. If so, it's likely CML patients won't be the only or even the first to gain from the new treatment strategy.

"It will take time because people with CML already do pretty well," he says. But β-catenin inhibitor
'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
2. New drug prevents spread of human prostate cancer cells
3. $4.2 million grant helps plan, launch first Alzheimers prevention trials
4. How cost effective are US cancer prevention services?
5. Could Statins Help Prevent Pneumonia?
6. Closing hole in the heart no better than drugs in preventing strokes
7. Study finds expensive procedure no more effective than medical therapy to prevent strokes
8. Nearly 800,000 deaths prevented due to declines in smoking
9. Study: US tobacco-control efforts prevented nearly 800,000 cancer deaths between 1975 and 2000
10. Ob-gyns can prevent negative health impacts of environmental chemicals
11. Gene chip invented by CHOP scientist pinpoints new target to prevent heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... pink race gear on e Bay in favor of Susan ... Awareness month and pink is// the symbolic color of Breast ... Racing to create exclusive warriors in pink livery with exclusive ... the eBay auction. ,Parts of the Warrior in ...
... a team of researchers from the Edinburgh University, the risk ... a variant of a gene called// neuregulin. ,This ... high risk of developing schizophrenia were monitored for 10 years ... the volunteers had 2 or more relatives affected by this ...
... packets of counterfeit condoms of Durex best-selling 'extra safe' range ... ,A Durex spokeswoman stated that the company could not 'guarantee ... that were on sale in UK was also unknown,These counterfeits ... When tests were conducted at the company's laboratories it was ...
... which could protect children from meningococcal disease is being ... disease has not been// available. ,The researchers, ... Child Health Research and Princess Margaret Hospital for Children, ... meningococcal B strain which is the most common. It is ...
... Monday called for fast tracking of the approval ... effective against extremely drug resistant// tuberculosis(XDR-TB) which is ... ,MSF otherwise called Doctors Without Borders(DWB) has ... Food and Drug Administraton(USFDA) and European Medicines Agency ...
... must have spice in every Indian home now finds itself ... uses to fight// many tubborn inflammations and degenerative disorders thus ... scripts of Ayurveda. ,According to a recent study ... Janet L. Funk, MD, working with Barbara N. Timmermann, PhD ...
Cached Medicine News:Health News:Gene Variant associated with Schizophrenia identified 2Health News:Faster Approval Procedures Urged For New TB Drugs 2
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... found, results showed CYPHER(R) Stent ... had lower mortality and heart attack rates, ... patient data from a two-year randomized controlled trial comparing,the ... no,statistically significant differences in safety outcomes between the two,drug- ...
... Clinical investigators at the,European Society of Cardiology Congress ... Coronary Stent continued to,provide clinical benefits compared to a ... years of follow-up with no differences in safety. ... arm of the,study continued to be significantly less likely ...
Cached Medicine Technology:Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 2Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 3Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
Passive heat and moisture exchangers for respiratory applications....
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 500, HME...
Medicine Products: